DECODING THE INTERACTIONS BETWEEN T CELL RECEPTORS AND PEPTIDE-MHC
DECODING THE INTERACTIONS BETWEEN T CELL RECEPTORS AND PEPTIDE-MHC
批准号:
10682160
负责人:
Paul G. Thomas
金额:
$89.07万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
未结题
起止时间:
2018-06-20 至 2028-05-31
关键词:
3-DimensionalAddressAntigensAwardBindingBiologicalCellsCollaborationsCollectionComplexDataData SetDatabasesDiagnosticEpitopesGene ExpressionGenetic TranscriptionGoalsHumanImmuneImmunologistIndividualInfectionLibrariesMajor Histocompatibility ComplexMethodsModelingNaturePathologicPeptide ReceptorPeptide/MHC ComplexPeptidesPeripheral Blood Mononuclear CellProductivityProteinsProtocols documentationRecording of previous eventsReportingSamplingSourceSpecificityStructureT ChainT-Cell Antigen Receptor SpecificityT-Cell ReceptorTCR ActivationTherapeuticTrainingWorkcohortcombinatorialcomplex datacomputer frameworkexperimental studyimprovedinnovationnovelnovel strategiespathogenprediction algorithmpredictive modelingprogramsprotein protein interactionreceptortool
中文摘要
总结
同源肽-主要组织相容性复合物的常规TCR识别
pMHC是病原体和病理相关自身蛋白的适应性免疫识别的核心。
尽管使用AlphaFold等工具在蛋白质-蛋白质相互作用的结构预测方面取得了实质性进展,
和RoseTTAFold,从TCR序列从头预测TCR特异性(靶pMHC)尚未被证实。
实现了事实上,在最大的策划TCR特异性数据库中,只有约105个独特的TCR:pMHC
已经策划了分配,并且这些集中在<100个独特的pMHC表位上。在我们之前的工作中,
我们确定,需要超过200个识别相同表位的独特受体才能可靠地预测
以前未观察到的受体是否属于同一特异性组。这项工作表明,
一旦数据足够密集,特异性的局部预测就变得可行。因此,目前
可用数据的稀疏性质是推进该领域的主要限制。因此,我们的中央
一个假设是,推进TCR特异性的预测模型需要显著增加TCR特异性,
策划的TCR-pMHC数据的规模和多样性,这反过来又需要新的方法,
生成如此有用的数据集。在三个目标中,我们将解决目前表位的主要局限性,
发现和TCR表征管道。在目标1中,我们将改进关联单链的方法
TCR序列与特异性肽的结合,用于生成精心策划的TCRα或TCRβ关联的大型文库
单个抗原决定簇。除了支持我们的中心目标外,这些数据还将具有显著的独立性。
用于免疫分析和诊断。在目标2中,我们将建立分配配对链的方法
从单细胞实验到表位库的TCR β数据,扩展了我们最近报道的反向表位
发现管道。目标3将整合公共数据和目标1和2产生的数据,
结构和计算方法来产生改进的从头特异性预测算法。
这些目标将通过访问我们收集的纵向采样的PBMC来实现,这些PBMC来自>4000
来自不同祖先和感染史的精心策划的队列中的人类。
英文摘要
Summary
Conventional ɑβ T cell receptor (TCR) recognition of a cognate peptide-Major Histocompatibility Complex
(pMHC) is central to adaptive immune recognition of pathogens and pathologically associated self-proteins.
Despite substantial progress in structural prediction of protein-protein interactions with tools such as AlphaFold
and RoseTTAFold, de novo prediction of TCR specificity (target pMHC) from TCR sequence has not yet been
realized. Indeed, within the largest databases of curated TCR specificities, only ~105 unique TCR:pMHC
assignments have been curated, and these are focused on <100 unique pMHC epitopes. In our previous work,
we established that >200 unique receptors recognizing the same epitope are required to confidently predict
whether a previously unobserved receptor belongs to the same specificity group. This work demonstrates that
once data are sufficiently dense, local prediction of specificity becomes feasible. It follows that the current
sparse nature of the available data is the major restriction to advancing the field. Thus, our central
hypothesis is that advancing predictive models for TCR specificity requires a dramatic increase in the
magnitude and diversity of curated TCR-pMHC data, which in turn requires new approaches for
generating such useful data sets. In three Aims, we will address major limitations of the current epitope
discovery and TCR characterization pipelines. In Aim 1, we will improve methods for relating single chain
TCR sequences to specific peptides for generating large libraries of well-curated TCRα or TCRβ associations
with individual epitopes. In addition to supporting our central goal, these data will have significant independent
utility for immune profiling and diagnostics. In Aim 2, we will establish methods for assigning paired chain
TCRɑβ data from single cell experiments to epitope pools, extending our recently reported reverse epitope
discovery pipeline. Aim 3 will integrate public data and the data generated in Aims 1 and 2, with novel
structural and computational approaches to generate improved de novo specificity prediction algorithms.
These Aims will be accomplished by accessing our collection of longitudinally sampled PBMCs from >4000
humans across well-curated cohorts from diverse ancestries and infection histories.
期刊论文(23)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.coisb.2018.09.005
发表时间:
2018-09
期刊:
Current opinion in systems biology
影响因子:
3.7
作者:
[Vanessa Venturi;P. Thomas]
通讯作者:
Vanessa Venturi;P. Thomas
Immune responses in COVID-19 respiratory tract and blood reveal mechanisms of disease severity.
COVID-19 呼吸道和血液中的免疫反应揭示了疾病严重程度的机制。
DOI:
10.21203/rs.3.rs-802084/v1
发表时间:
2021
期刊:
Research square
影响因子:
--
作者:
[Zhang,Wuji, Chua,Brendon, Selva,Kevin, Kedzierski,Lukasz, Ashhurst,Thomas, Haycroft,Ebene, Shoffner,Suzanne, Hensen,Luca, Boyd,David, James,Fiona, Mouhtouris,Effie, Kwong,Jason, Chua,Kyra, Drewett,George, Copaescu,Ana, Dobson,Julie, Rowntr]
通讯作者:
Rowntr
DOI:
10.3390/ijms21238903
发表时间:
2020-11-24
期刊:
International journal of molecular sciences
影响因子:
5.6
作者:
[Clark BL, Thomas PG]
通讯作者:
Thomas PG
DOI:
10.1038/s41587-021-00989-2
发表时间:
2022-01
期刊:
Nature biotechnology
影响因子:
46.9
作者:
[Schattgen SA, Guion K, Crawford JC, Souquette A, Barrio AM, Stubbington MJT, Thomas PG, Bradley P]
通讯作者:
Bradley P
DOI:
10.1038/s41467-021-23018-x
发表时间:
2021-05-11
期刊:
Nature communications
影响因子:
16.6
作者:
[Nguyen THO, Koutsakos M, van de Sandt CE, Crawford JC, Loh L, Sant S, Grzelak L, Allen EK, Brahm T, Clemens EB, Auladell M, Hensen L, Wang Z, Nüssing S, Jia X, Günther P, Wheatley AK, Kent SJ, Aban M, Deng YM, Laurie KL, Hurt AC, Gras S, Rossjohn J, Crowe J, Xu J, Jackson D, Brown LE, La Gruta N, Chen W, Doherty PC, Turner SJ, Kotsimbos TC, Thomas PG, Cheng AC, Kedzierska K]
通讯作者:
Kedzierska K
共 16 条
Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma
-
批准号:10609918
-
项目类别:
-
资助金额:$70.3万
-
财政年份:2023
-
负责人:Paul G. Thomas
-
依托单位:
Neoantigen-specific T cell responses for Fibrolamellar Hepatocellular Carcinoma
-
批准号:10467512
-
项目类别:
-
资助金额:$73.33万
-
财政年份:2022
-
负责人:Paul G. Thomas
-
依托单位:
Decoding the interactions between T cell receptors and peptide-MHC
-
批准号:10406323
-
项目类别:
-
资助金额:$68.19万
-
财政年份:2018
-
负责人:Paul G. Thomas
-
依托单位:
Decoding the interactions between T cell receptors and peptide-MHC
-
批准号:10158266
-
项目类别:
-
资助金额:$68.19万
-
财政年份:2018
-
负责人:Paul G. Thomas
-
依托单位:
A protective role for gamma delta T cells in respiratory infection
-
批准号:9234456
-
项目类别:
-
资助金额:$45.45万
-
财政年份:2016
-
负责人:Paul G. Thomas
-
依托单位:
A protective role for gamma delta T cells in respiratory infection
-
批准号:9113835
-
项目类别:
-
资助金额:$45.84万
-
财政年份:2016
-
负责人:Paul G. Thomas
-
依托单位:
Mechanisms to diversify repertoire and modify T cell activity after infection
-
批准号:8573498
-
项目类别:
-
资助金额:$45.04万
-
财政年份:2013
-
负责人:Paul G. Thomas
-
依托单位:
Mechanisms to diversify repertoire and modify T cell activity after infection
-
批准号:8709989
-
项目类别:
-
资助金额:$45.54万
-
财政年份:2013
-
负责人:Paul G. Thomas
-
依托单位:
Mechanisms to diversify repertoire and modify T cell activity after infection
-
批准号:9319117
-
项目类别:
-
资助金额:$45.54万
-
财政年份:2013
-
负责人:Paul G. Thomas
-
依托单位:
Quantifying and modeling influenza viral dynamics and host responses
-
批准号:8321729
-
项目类别:
-
资助金额:$64.81万
-
财政年份:2011
-
负责人:Paul G. Thomas
-
依托单位:
Immunodominance hierarchies and compensation in influenza specific CD8+ T cell re
-
批准号:7530465
-
项目类别:
-
资助金额:$16.2万
-
财政年份:2009
-
负责人:Paul G. Thomas
-
依托单位:
Immunodominance hierarchies and compensation in influenza specific CD8+ T cell re
-
批准号:7937978
-
项目类别:
-
资助金额:$10.8万
-
财政年份:2009
-
负责人:Paul G. Thomas
-
依托单位:
Antigen-specific CD4+ T cell responses to influenza
-
批准号:6936903
-
项目类别:
-
资助金额:$4.4万
-
财政年份:2005
-
负责人:Paul G. Thomas
-
依托单位:
Antigen-specific CD4+ T cell responses to influenza
-
批准号:7084639
-
项目类别:
-
资助金额:$4.88万
-
财政年份:2005
-
负责人:Paul G. Thomas
-
依托单位:
Antigen-specific CD4+ T cell responses to influenza
-
批准号:7257111
-
项目类别:
-
资助金额:$5.04万
-
财政年份:2005
-
负责人:Paul G. Thomas
-
依托单位:
海外基金